written on 28.02.2014

Buoyant Bayer ups key drug sales forecast


Adjusted EBITDA in the last three months of 2013 slipped to €1.77bn, dampened by a weak Japanese yen and emerging-market currencies, the company said. The decline was attributed to "substantial negative currency effects, as well as higher research…

Latest Reports